



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
10.01.2001 Bulletin 2001/02

(21) Application number: 95921063.4

(22) Date of filing: 07.06.1995

(51) Int Cl.7: **C12N 15/14, C12N 1/19**

(86) International application number:
PCT/GB95/01317

(87) International publication number:
WO 95/33833 (14.12.1995 Gazette 1995/53)

(54) **ALBUMIN EXPRESSION IN YEAST**
EXPRESSION VON ALBUMIN IN HEFE
EXPRESSION D'ALBUMINE DANS DES LEVURES

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GR IE IT LI LU MC NL PT
SE**

(30) Priority: 07.06.1994 GB 9411356

(43) Date of publication of application:
26.03.1997 Bulletin 1997/13

(73) Proprietor: **Delta Biotechnology Limited**
Nottingham NG7 1FD (GB)

(72) Inventors:
• **WOOD, Patricia Carol,**
Delta Biotechnology Limited
Nottingham NG7 1FD (GB)
• **QUIRK, Alan Victor, Delta Biotechnology Limited**
Nottingham NG7 1FD (GB)

(74) Representative: **Bassett, Richard Simon**
Eric Potter Clarkson,
Park View House,
58 The Ropewalk
Nottingham NG1 5DD (GB)

(56) References cited:
• **MOL GEN GENET, MAY 1993, 239 (1-2) P273-80,**
GERMANY, RUSSO P ET AL 'Dual regulation by
heat and nutrient stress of the yeast HSP150
gene encoding a secretory glycoprotein.'
• **BIOTECHNOLOGY, vol. 8, 1990 NEW YORK US,**
pages 42-46, SLEEP D. ET AL. 'The secretion of
human serum albumin from the yeast
Sachcharomyces cerevisiae using five different
leader sequences' cited in the application

BEST AVAILABLE COPY

EP 0 764 209 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Field of the Invention**

5 [0001] The present invention relates to the production of heterologous proteins by yeast species and more particularly to an adaptation of the yeast in which the protein is produced.

Background and Prior Art

10 [0002] In recent years, yeasts have been widely used as host organisms for the production of heterologous proteins (reviewed by Romanos *et al*, 1992), including recombinant human albumin (rHA) (Sleep *et al*, 1990, 1991; Fleer *et al*, 1991). Yeasts are readily amenable to genetic manipulation, can be grown to high cell density on simple media, and as eukaryotes are suitable for the production of secreted as well as cytosolic proteins.

15 [0003] When yeasts are utilised to produce a desired heterologous protein by secretion into the growth medium, a large number of host-derived proteins may also be present, including other proteins secreted by the host but also intracellular proteins present in the supernatant as the result of leakage from cells or cell lysis. In processes in which the protein is not secreted, there is of course an even higher level of contamination with intracellular yeast proteins. It is necessary to purify the desired protein and to remove these contaminating proteins from the preparation; such methods have been disclosed in WO 92/04367 and EP 524 681. The majority of contaminating proteins will have
20 physicochemical properties sufficiently different from the desired protein to permit efficient separation by standard techniques, such as ion exchange or size exclusion chromatography. The prior art gives the impression that such proteins can be satisfactorily removed by such techniques; see, for example EP 524 681 (Gist-brocades), EP 570 916 (Green Cross) and EP 464 590 (Green Cross). Indeed, we have developed sophisticated chromatographic techniques (unpublished) to remove contaminating proteins from desired proteins.

Summary of the Invention

25 [0004] We have now also adopted a different approach and have identified the gene responsible for a protein, namely the *HSP150* gene, which co-purifies with recombinant albumin (rA). In accordance with the invention, we eliminate the contaminating protein from the initial fermentation, rather than develop highly sophisticated and complex means of removal during purification. This protein was not previously known to be a co-purifying contaminant.

30 [0005] In one aspect of the invention, the *HSP150* gene is functionally deleted from the genome of the host. This has not caused any detrimental effects on production of the desired protein and removes a potential contaminant that has proven difficult to remove by standard purification techniques. Despite the presence of at least two closely related genes encoding proteins very similar to Hsp150, *PIR1* and *PIR3*, in such modified yeast, rA purified from these organisms does not contain detectable levels of any protein from this family.

35 [0006] The *S. cerevisiae* Hsp150 protein was originally described by Russo *et al* (1992) and was shown to be produced constitutively, to be extensively O-glycosylated and to be secreted efficiently into the growth medium. A 7-fold increase in the level of Hsp150 protein was seen when cells grown at 28°C were shifted to 37°C. Makarow has proposed preparing fusions of Hsp150 (or fragments thereof) and a desired protein, in order to achieve enhanced, controllable secretion (WO 93/18167). The *HSP150* gene encodes a primary translation product of 413 amino acids, including an N-terminal secretion signal sequence of 18 amino acids that is not present in the mature protein. A further post-translational processing event occurs C-terminal to a pair of basic residues to yield two subunits of 54 and 341 amino acids which remain associated. The 341 amino acid subunit contains 11 tandem repeats of a 19 amino acid sequence, the
40 function of which is unknown. Homologues of the *HSP150* gene were found in *Torulaspora delbrueckii*, *Kluyveromyces marxianus* and *Schizosaccharomyces pombe* (Russo *et al*, 1992).

45 [0007] The same protein has been designated the PIR2 protein by Toh-e *et al* (1993). The *HSP150/PIR2* gene was shown to be a member of a family of at least three genes (*PIR1*, *PIR2* and *PIR3*) all of which contain similar internal tandem repeats of approximately 19 amino acids. Homologues of the *PIR* genes were shown to be present also in
50 *Kluyveromyces lactis* and *Zygosaccharomyces rouxii* (Toh-e *et al*, 1993). Disruption of the *HSP150/PIR2* gene showed that this is not an essential gene (Russo *et al*, 1992; Toh-e *et al*, 1993).

[0008] In this specification we refer to rA as the desired protein.

55 [0009] Our studies have revealed that the Hsp150 protein is inefficiently separated from rHA by ion exchange chromatography. Surprisingly, however, Hsp150 does not appear in the fraction equivalent to the rHA fraction when rHA is absent. For example, when rHA-containing culture supernatant is passed through a cation exchange column under conditions which ensure binding of the rHA to the column (eg pH4.5, conductivity < 7mS), Hsp150 also binds to the column and is eluted under the same conditions as rHA and thus contaminates the rHA preparation. However, when culture supernatant from a yeast that does not secrete rHA is passed through such a column under the same conditions,

the Hsp150 protein does not bind to the matrix but passes straight through the column. The eluate fraction does not contain Hsp150 in the absence of rHA. Similarly, the Hsp150 protein does not bind to an anion exchange column run under conditions which would result in binding of albumin (eg pH5.5, 1.5mS) in the absence of rHA, but is present in the rHA eluate fraction when rHA is present. Surprisingly, we have found that the presence of rHA in culture supernatant significantly alters the behaviour of some yeast proteins during chromatographic purification of the rHA such that proteins with physico-chemical properties which indicate that they would be separated from albumin by, for instance, ion exchange chromatography in fact contaminate the rHA preparation and are difficult to remove.

[0010] One aspect of the invention provides a process for preparing a recombinant albumin from yeast, comprising culturing the yeast and obtaining the albumin characterised in that the yeast is deficient in heat shock protein 150 (Hsp150).

[0011] The most convenient way of achieving this is to create a yeast which has a defect in its genome such that a reduced level of the Hsp150 protein is produced. For example, there may be a deletion, insertion or transposition in the coding sequence or the regulatory regions (or in another gene regulating the expression of the Hsp150 gene) such that little or no Hsp150 protein is produced. Alternatively, the yeast could be transformed to produce an anti-Hsp150 agent, such as an anti-Hsp150 antibody.

[0012] To modify the *HSP150* gene so that a reduced level of co-purifying protein is produced, site-directed mutagenesis or other known techniques can be employed to create single or multiple mutations, such as replacements, insertions, deletions, and transpositions, as described in Botstein and Shortle, "Strategies and Applications of *In Vitro* Mutagenesis", *Science*, 229: 193-210 (1985), which is incorporated herein by reference. Suitable mutations include chain termination mutations (clearly stop codons introduced near the 3' end might have insufficient effect on the gene product to be of benefit; the person skilled in the art will readily be able to create a mutation in, say, the 5' three quarters of the coding sequence), point mutations that alter the reading frame, small to large deletions of coding sequence, mutations in the promoter or terminator that affect gene expression and mutations that de-stabilize the mRNA. Some desirable point mutations or specific amino acid substitutions may affect chromatographic behaviour by altering the charge distribution. Hence, the protein produced has a similar primary amino acid sequence to that of native Hsp150, but is functionally distinct such that it will not co-purify with the desired protein. Such a modified protein is not regarded as being Hsp150. Specific mutations can be introduced by an extension of the gene disruption technique known as gene transplacement (Winston, F. *et al* (1983) *Methods Enzymol.* 101, 211-228).

[0013] Any polypeptides inserted into the Hsp150 protein should not be, and should not create, ligands for the desired protein. Those skilled in the art can readily determine, by simple binding assays, whether a ligand has been used or created. Generally one uses a selectable marker to disrupt a gene sequence, but this need not be the case, particularly if one can detect the disruption event phenotypically. In many instances the insertion of the intervening sequence will be such that a stop codon is present in frame with the Hsp150 sequence and the inserted coding sequence is not translated. Alternatively the inserted sequence may be in a different reading frame to Hsp150.

[0014] The gene may have one or more portions (optionally including regulatory regions, up to the whole gene) excised or inverted, or it may have a portion inserted, in order to result either in no production of protein from the *HSP150* locus or in the production of protein from the *HSP150* locus which does not co-purify with the desired protein.

[0015] Preferably, the yeast secretes the recombinant albumin which is then purified from the fermentation medium. The purification may take place elsewhere; hence, production of culture medium, containing albumin in which the level of Hsp150 protein is low or zero is an end in itself.

[0016] A protein is generally regarded as co-purifying with Hsp150 if the two are still associated after two dissimilar chromatographic separation techniques (one of which is affinity chromatography for the desired protein) or, if affinity chromatography is not used, if the proteins are still associated after three dissimilar steps (for example an anion exchange, a cation exchange and a gel permeation step).

[0017] Human serum albumin (HSA) is a protein of 585 amino acids that is present in human serum at a concentration of 35-45g L⁻¹ and represents about 60% of the total serum protein. HSA is responsible for a significant proportion of the osmotic pressure of serum, and also functions as a carrier of endogenous and exogenous ligands. It is used clinically in the treatment of patients with severe burns, shock, or blood loss, and at present is produced commercially by extraction from human blood. The production of recombinant human albumin (rHA) in microorganisms has been disclosed in EP 330 451 and EP 361 991.

[0018] The albumin may be a variant of normal HSA/rHA. By "variants" we include insertions, deletions and substitutions, either conservative or non-conservative, where such changes do not substantially alter the oncotic, useful ligand-binding or non-immunogenic properties of albumin. In particular, we include naturally-occurring polymorphic variants of human albumin; fragments of human albumin, for example those fragments disclosed in EP 322 094 (namely HSA (1-n), where n is 369 to 419); and fusions of albumin with other proteins, for example the kind disclosed in WO 90/13653.

[0019] By "conservative substitutions" is intended swaps within groups such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr.

[0020] A second main aspect of the invention provides a yeast transformed to express a recombinant albumin which will co-purify with Hsp150 in chromatographic techniques, characterised in that the yeast is deficient in such Hsp150.

[0021] In addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium.

[0022] The recombinant albumin is produced in conventional ways, for example from a coding sequence inserted in the yeast chromosome or on a free plasmid.

[0023] The yeasts are transformed with a coding sequence for the albumin in any of the usual ways, for example electroporation. Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol.* 194, 182.

[0024] Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct can be grown to produce the recombinant albumin. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* 98, 503 or Berent *et al* (1985) *Biotech.* 3, 208. Alternatively, the presence of the albumin in the supernatant can be detected using antibodies.

[0025] Useful yeast plasmid vectors include pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (Ylps) and incorporate the yeast selectable markers *HIS3*, *TRP1*, *LEU2* and *URA3*. Plasmids pRS413-416 are Yeast Centromere plasmids (YCps).

[0026] A variety of methods have been developed to operably link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

[0027] Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or *E. coli* DNA polymerase I, enzymes that remove protruding, 3'-single-stranded termini with their 3'-5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.

[0028] The combination of these activities therefore generates blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

[0029] Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

[0030] A desirable way to modify the DNA in accordance with the invention is to use the polymerase chain reaction as disclosed by Saiki *et al* (1988) *Science* 239, 487-491. In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

[0031] Any yeast which produces an Hsp150 protein can be modified in accordance with the invention. Exemplary genera of yeast contemplated to be useful in the practice of the present invention are *Pichia* (*Hansenula*), *Saccharomyces*, *Kluyveromyces*, *Candida*, *Torulopsis*, *Torulaspora*, *Schizosaccharomyces*, *Citeromyces*, *Pachysolen*, *Debaromyces*, *Metschnikowia*, *Rhodosporidium*, *Leucosporidium*, *Botryosaccharus*, *Sporidiobolus*, *Endomycopsis*, and the like.

[0032] Preferred genera are those selected from the group consisting of *Saccharomyces*, *Schizosaccharomyces*, *Kluyveromyces*, and *Torulaspora*. Examples of *Saccharomyces* spp. are *S. cerevisiae*, *S. italicus* and *S. rouxii*. Examples of *Kluyveromyces* spp. are *K. fragilis*, *K. lactis* and *K. marxianus*. A suitable *Torulaspora* species is *T. delbrueckii*. Examples of *Pichia* (*Hansenula*) spp. are *P. angusta* (formerly *H. polymorpha*), *P. anomala* (formerly *H. anomala*) and *P. pastoris*.

[0033] Homologues of *HSP150* have already been shown to be present in a wide range of different yeast genera: *Torulaspora* sp., *Kluyveromyces* sp., *Schizosaccharomyces* sp. and *Zygosaccharomyces* sp. (Russo *et al*, 1992; Tohe *et al*, 1993). In addition, our own studies have shown by Southern blotting that *Pichia* sp. possess a homologue of *HSP150*.

[0034] Methods for the transformation of *S. cerevisiae* are taught generally in EP 251 744, EP 258 067 and WO 90/01063, all of which are incorporated herein by reference.

[0035] Suitable promoters for *S. cerevisiae* include those associated with the *PGK1* gene, *GAL1* or *GAL10* genes, *CYC1*, *PHO5*, *TRP1*, *ADH1*, *ADH2*, the genes for glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, triose phosphate isomerase, phosphoglucose isomerase, glucokinase, α -mating

factor pheromone, α -mating factor pheromone, the *PRB1* promoter, the *GUT2* promoter, the *GPD1* promoter, and hybrid promoters involving hybrids of parts of 5' regulatory regions with parts of 5' regulatory regions of other promoters or with upstream activation sites (eg the promoter of EP-A-258 067).

[0036] Convenient regulatable promoters for use in *Schizosaccharomyces pombe* are the thiamine-repressible promoter from the *nmt* gene as described by Maundrell (1990) *J. Biol. Chem.* 265, 10857-10864 and the glucose-repressible *fbp1* gene promoter as described by Hoffman & Winston (1990) *Genetics* 124, 807-816.

[0037] Methods of transforming *Pichia* for expression of foreign genes are taught in, for example, Cregg *et al* (1993), and various Phillips patents (eg US 4 857 467, incorporated herein by reference), and *Pichia* expression kits are commercially available from Invitrogen BV, Leek, Netherlands, and Invitrogen Corp., San Diego, California. Suitable promoters include *AOX1* and *AOX2*.

[0038] The Gellissen *et al* (1992) paper mentioned above and Gleeson *et al* (1986) *J. Gen. Microbiol.* 132, 3459-3465 include information on *Hansenula* vectors and transformation, suitable promoters being *MOX1* and *FMD1*; whilst EP 361 991, Fleer *et al* (1991) and other publications from Rhône-Poulenc Rorer teach how to express foreign proteins in *Kluyveromyces* spp., a suitable promoter being *PGK1*.

[0039] The transcription termination signal is preferably the 3' flanking sequence of a eukaryotic gene which contains proper signals for transcription termination and polyadenylation. Suitable 3' flanking sequences may, for example, be those of the gene naturally linked to the expression control sequence used, ie may correspond to the promoter. Alternatively, they may be different in which case the termination signal of the *S. cerevisiae ADH1* gene is preferred.

[0040] The recombinant albumin may be initially expressed with a secretion leader sequence, which may be any leader effective in the yeast chosen. Leaders useful in *S. cerevisiae* include that from the mating factor α polypeptide (MF α -1) and the hybrid leaders of EP-A-387 319. Such leaders (or signals) are cleaved by the yeast before the mature albumin is released into the surrounding medium. Further such leaders include those of *S. cerevisiae* invertase (*SUC2*) disclosed in JP 62-096086 (granted as 91/036516), acid phosphatase (*PHO5*), the pre-sequence of MF α -1, β -glucanase (*BGL2*) and killer toxin; *S. diastaticus* glucoamylase II; *S. carlsbergensis* α -galactosidase (*MEL1*); *K. lactis* killer toxin; and *Candida* glucoamylase.

Detailed Description of the Invention

[0041] Preferred aspects of the invention will now be described in more detail, with reference to the accompanying drawings, in which

Figure 1 is a scheme showing the preparation of an *EcoRI* *HSP150-URA3-HSP150* fragment used to transform a yeast strain (DBU3) and disrupt the *HSP150* gene (Example 1); and

Figure 2 is a scheme showing the preparation of a further *EcoRI* fragment used to remove the *HSP150* coding sequence altogether (Example 2).

[0042] All standard recombinant DNA procedures are as described in Sambrook *et al* (1989) unless otherwise stated. The DNA sequences encoding rHA are derived from the cDNA disclosed in EP 201 239.

Example 1

[0043] The *HSP150* gene was mutated by the process of gene disruption (Rothstein, 1983) which effectively deleted part of the *HSP150* coding sequence, thereby preventing the production of Hsp150.

[0044] Four oligonucleotides suitable for the PCR amplification of the 5' and 3' ends of the *HSP150* gene (Russo *et al*, 1992) were synthesized using an Applied Biosystems 380B Oligonucleotide Synthesizer.

5' End

LRE45: 5' -CTATTTCTATTTTCGGAATTCTTAAAGACAAAAAGCTC-3'

LRE46: 5' -GGCTGTGGTGCTGCAGATGATGCGCTGG-3'

3' End

LRE47: 5' -GCTACTTCCGCTTCTGCAGCCGCTACCTCC-3'

LRE48: 5' -GCCGTGTAGCGAGGGAATTCTGTGGTCACGATCACTCG-3'

[0045] Note, LRE45 and LRE48 contain changes in the *HSP150* gene sequence so as to introduce *EcoRI* sites into the 5' or the 3' end of the *HSP150* gene PCR products. LRE46 and LRE47 both contain *PstI* sites naturally present in the *HSP150* gene sequence (SEQ 1).

[0046] PCR was carried out to amplify individually the 5' and 3' ends of the *HSP150* gene, using LRE45 and LRE46 or LRE47 and LRE48 respectively, from the DNA from *S. cerevisiae* genomic DNA (Clontech Laboratories, Inc.).

[0047] Conditions were as follows: 1 µg/ml genomic DNA, = 1.2×10^{-10} moles of each primer, denature at 94°C for 61 seconds, anneal at 37°C for 121 seconds, DNA synthesis at 72°C for 181 seconds for 30 cycles, with a 10 second extension to the DNA synthesis step after each cycle, followed by a 4°C soak. PCR was carried out using a Perkin-Elmer-Cetus Thermal cycler and a Perkin-Elmer-Cetus PCR kit was used according to the manufacturer's recommendations. PCR products were analysed by gel electrophoresis and were found to be of the expected size. Each PCR product was digested with *EcoRI* and *PstI* and cloned into *EcoRI/PstI* digested pUC19 (Yanisch-Perron *et al*, 1985) to form pAYE503 (containing the 5' end of the *HSP150* gene) and pAYE504 (containing the 3' end of the *HSP150* gene) (see Fig. 1).

[0048] Plasmid DNA sequencing was carried out on pAYE503 and pAYE504 to confirm that the inserts were the desired sequences. pAYE503 and pAYE504 were digested with *EcoRI* and *HindIII* and the *HSP150* gene fragments were isolated and cloned together into pUC19XH (a derivative of pUC19 lacking a *HindIII* site in its polylinker) to form pAYE505. The *URA3* gene was isolated from YEp24 (Botstein *et al*, 1979) as a *HindIII* fragment and cloned into the *HindIII* site of pAYE505 to form pAYE506 (Fig. 1). pAYE506 contains a selectable marker (*URA3*) flanked by 5' and 3' regions of the *HSP150* gene.

[0049] To construct a strain lacking the capacity to produce HSP150, a *ura3* derivative of DB1 *cir*⁺ pAYE316 (Sleep *et al*, 1991) was obtained by random chemical mutagenesis and selection for resistance to 5-fluoro-orotic acid (Boeke *et al*, 1987). Plasmid pAYE316 is based on the 2 µm plasmid and contains a coding sequence for human albumin under the control of the yeast *PRB1* promoter, with an *ADH1* terminator and a *LEU2* selectable marker.

[0050] The strain was grown overnight in 100mL buffered minimal medium (Yeast Nitrogen Base [without amino acids, without ammonium sulphate, Difco], (NH₄)₂SO₄ 5g/L, citric acid monohydrate 6.09g/L, NaHPO₄ 20.16g/L, sucrose 20g/L, pH6.5) and the cells were collected by centrifugation and then washed once with sterile water. The cells were then resuspended in 10mL sterile water and 2mL aliquots were placed in separate 15mL Falcon tubes. A 5mg/mL solution of N-methyl-N'-nitro-N-nitrosoguanidine (NTG) was then added to the tubes as follows: 0µL, 20µL, 40µL, 80µL or 160µL. The cells were then incubated at 30°C for 20 min and then centrifuged and washed three times with sterile water. Finally, the cells were resuspended in 1mL YEP (1%w/v yeast extract, 2%w/v Bacto peptone) and stored at 4°C. The percentage of cells that survived the mutagenic treatment was determined by spreading dilutions of the samples on YEP plates containing 2%w/v sucrose and incubating at 30°C for 3 days. Cells from the treatment which gave approximately 50% survival were grown on YEP plates containing 2%w/v sucrose and then replica-plated onto YNB minimal medium containing 2%w/v sucrose and supplemented with 5-fluoro-orotic acid (1mg/mL) and uracil (50µg/mL). Colonies able to grow on this medium were purified, tested to verify that they were unable to grow in the absence of uracil supplementation and that this defect could be corrected by introduction of the *URA3* gene by transformation.

[0051] The *ura3* strain, DBU3 *cir*⁺ (pAYE316), was transformed with *EcoRI* digested pAYE506 and Ura⁺ transformants were selected. The disruption of the *HSP150* gene in these transformants was confirmed by Southern blot analysis using a fragment comprising the 5' and 3' ends of the *HSP150* gene (the *EcoRI* fragment from pAYE505) as a probe.

[0052] The yeast was then grown to high cell density by fed batch culture in minimal medium in a fermenter (Collins, 1990). Briefly, a fermenter of 10L working volume was filled to 5L with an initial batch medium containing 50 mL/L of a concentrated salts mixture (Table 1), 10 mL/L of a trace elements solution (Table 2), 50 mL/L of a vitamins mixture (Table 3) and 20 g/L sucrose. An equal volume of feed medium containing 100 mL/L of the salts mixture, 20 mL/L of the trace elements mixture, 100 mL/L of vitamins solution and 500 g/L sucrose was held in a separate reservoir connected to the fermenter by a metering pump. The pH was maintained at 5.7 ± 0.2 by the automatic addition of ammonium hydroxide or sulphuric acid, and the temperature was maintained at 30°C. The stirrer speed was adjusted to give a dissolved oxygen tension of > 20% air saturation at 1 v/v/min air flow rate.

Table 1.

Salts Mixture	
Chemical	Concentration (g/L)
KH ₂ PO ₄	114.0
MgSO ₄	12.0
CaCl ₂ .6H ₂ O	3.0
Na ₂ EDTA	2.0

Table 2.

Trace Elements Solution	
Chemical	Concentration (g/L)
ZnSO ₄ .7H ₂ O	3.0
FeSO ₄ .7H ₂ O	10.0
MnSO ₄ .4H ₂ O	3.2
CuSO ₄ .5H ₂ O	0.079
H ₃ BO ₃	1.5
KI	0.2
Na ₂ MoO ₄ .2H ₂ O	0.5
CoCl ₂ .6H ₂ O	0.56
H ₃ PO ₄	75mL/L

Table 3.

Vitamins Solution	
Chemical	Concentration (g/L)
Ca pantothenate	1.6
Nicotinic acid	1.2
<i>m</i> -inositol	12.8
Thiamine HCl	0.32
Pyridoxine HCl	0.8
Biotin	0.008

[0053] The fermenter was inoculated with 100 mL of an overnight culture of *S. cerevisiae* grown in buffered minimal medium (Yeast nitrogen base [without amino acids, without ammonium sulphate, Difco] 1.7 g/L, (NH₄)₂SO₄ 5 g/L, citric acid monohydrate 6.09 g/L, Na₂HPO₄ 20.16 g/L, sucrose 20 g/L, pH6.5). The initial batch fermentation proceeded until the carbon source had been consumed, at which point the metering pump was switched on and the addition of feed was computer controlled (the micro MFCS system, B. Braun, Melsungen, Germany) using an algorithm based on that developed by Wang *et al* (1979). A mass spectrometer was used in conjunction with the computer control system to monitor the off gases from the fermentation and to control the addition of feed to maintain a set growth rate (eg 0.1 h⁻¹). Maximum conversion of carbon substrate into biomass is achieved by maintaining the respiratory coefficient below 1.2 (Collins, 1990) and, by this means, cell densities of approximately 100 g/L cell dry weight can be achieved.

[0054] The fermentation broth was centrifuged to remove the cells and then subjected to affinity chromatographic purification as follows. The culture supernatant was passed through a Cibacron Blue F3GA Sepharose column (Pharmacia) which was then washed with 0.1M phosphate glycine buffer, pH8.0. The rHA was then eluted from the column with 2M NaCl, 0.1M phosphate glycine, pH8.0. The albumin may alternatively be purified from the culture medium by

any of the variety of known techniques for purifying albumin from serum or fermentation culture medium, for example those disclosed in WO 92/04367, Maurel *et al* (1989), Curling (1980) and EP 524 681.

[0055] Analysis of rHA purified from *Hsp150* strains revealed that no HSP150 protein was present in these samples. HSP150 protein is determined using prior art techniques such as ELISA or Western blotting.

[0056] Anti-HSP150 antibodies are disclosed in Russo *et al* (1992) *Proc. Nat. Acad. Sci. (USA)* 89, 3671-3675.

Example 2

[0057] The *HSP150* protein coding sequence was deleted by using alternative fragments of the cloned *HSP150* sequences as follows.

[0058] The *URA3 HindIII* fragment from YEp24 (see Example 1) was cloned into pIC19R (Marsh J.L. *et al* (1984) *Gene* 32, 481-485) at *HindIII* to form pAYE601 and then excised as a *SalI/ClaI* fragment and inserted into pAYE505 at the *XhoI* and *ClaI* sites to form pAYE602 (Fig 2). This plasmid was digested with *EcoRI* and then used to transform DBU3 *cir*⁺ (pAYE316), selecting for Ura⁺ transformants. The disruption of the *HSP150* gene in these transformants was confirmed by Southern blot analysis as described in Example 1.

[0059] Thus, in this example, the whole of the *HSP150* coding sequence is removed, whereas in Example 1 the sequence is disrupted to yield non-functional protein.

Example 3

[0060] Southern blotting has revealed an *Hsp150* homologue in *Hansenula polymorpha* (now called *Pichia angusta*). The *P. angusta* gene may be functionally deleted by ways analogous to those in Examples 1 and 2.

References

[0061]

Boeke, J. D. *et al* (1987) *Methods Enzymol.* 154, 164-175.

Botstein, D. *et al* (1979) *Gene* 8, 17-24.

Collins, S.H. (1990) In *Protein Production by Biotechnology* (Harris, T.J.R., ed.) pp 61-77, Elsevier, Barking, Essex.

Curling (1980) "Albumin Purification by Ion Exchange Chromatography", in "Methods of Plasma Protein Purification", Ed. Curling, J.M., Academic Press, London.

Fleer, R. *et al* (1991) *Bio/Technology* 9, 968-975.

Maurel *et al* (1989) "Biotechnology of Plasma Proteins", Colloque INSERM 175, 19-24.

Romanos, M. *et al* (1992) *Yeast* 8, 423-488.

Rothstein, R. J. (1983) *Methods Enzymol.* 101, 202-211.

Russo, P. *et al* (1992) *Proc. Natl. Acad. Sci. USA* 89, 3671-3675.

Sambrook, J. *et al* (1989) *Molecular Cloning: a Laboratory Manual*, 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. NY.

Sleep, D. *et al* (1991) *Bio/Technology* 9, 183-187.

Toh-e *et al* (1993) *Yeast* 9, 481-494.

Wang, H.Y. *et al* (1979) *Biotechnology & Bioeng.* 21, 975

Yanisch-Perron, C. *et al* (1985) *Gene* 33, 103-119.

SEQUENCE LISTING

[0062]

5 (1) GENERAL INFORMATION:

(i) APPLICANT:

- 10 (A) NAME: Delta Biotechnology Limited
(B) STREET: Castle Court, Castle Boulevard
(C) CITY: Nottingham
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): NG7 1FD

15 (ii) TITLE OF INVENTION: Yeast Strains

(iii) NUMBER OF SEQUENCES: 6

(iv) COMPUTER READABLE FORM:

- 20 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

25 (vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9411356.0
(B) FILING DATE: 07-JUN-1994

30 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- 45 (A) NAME/KEY: misc_feature
(B) LOCATION: 1..40
(D) OTHER INFORMATION: /note= "Oligonucleotide for PCR amplification of 5' end of Hsp150 gene."

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTATTTCTTA TTTCGGGAAT TCTTAAAGAC AAAAAAGCTC
40

55

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 1..28
(D) OTHER INFORMATION: /note= "Oligonucleotide for PCR amplification of the 5' end of the Hsp150 gene."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGCTGTGGTG CTGCAGATGA TGCGCTGG
28

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 1..30
(D) OTHER INFORMATION: /note= "Oligonucleotide for PCR amplification of 3' end of the Hsp150 gene."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCTACTTCCG CTTCTGCAGC CGCTACCTCC
30

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..38

(D) OTHER INFORMATION: /note= "Oligonucleotide for PCR amplification of the 3' end of the Hsp150 gene."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCCGTGTAGC GAGGGAATTC TGTGGTCACG ATCACTCG
38

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2048 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 397..1638

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

AGTGATCTTA CTATTCCTA TTTCGGAAAT TATTAAAGAC
 AAAAAAGCTC ATTAATGGCT 60

5

TTCCGTCTGT AGTGATAAGT CGCCAACCTCA GCCTAATTTT
 TCATTTCTTT ACCAGATCAG 120

10

GAAAACTAAT AGTACAAATG AGTGTTTTCT CAAGCGGAAC
 ACCACATTTT GAGCTAAATT 180

15

TAGATTTTGG TCAAAATAAG AAAGATCCTA AAAAAGGAAT
 GGTGGTGAA AAATTTATTA 240

GCTTGAATGG TAGGAATCCT CGAGATATAA AAGGAACACT
 TGAAGTCTAA CGACAATCAA 300

20

TTTCGATTAT GTCCTTCCTT TTACCTCAAA GCTCAAAAAA
 ATATCAATAA GAAACTCATA 360

25

TTCTTTTCT AACCTAGTA CAATAATAAT AATATA ATG CAA
 TAC AAA AAG ACT 414

Met Gln Tyr Lys Lys Thr
 1 5

30

TTG GTT GCC TCT GCT TTG GCC GCT ACT ACA TTG GCC GCC
 TAT GCT CCA 462

Leu Val Ala Ser Ala Leu Ala Ala Thr Thr Leu Ala Ala Tyr Ala Pro

35

10 15 20

TCT GAG CCT TGG TCC ACT TTG ACT CCA ACA GCC ACT TAC
 AGC GGT GGT 510

40

45

50

55

Ser Glu Pro Trp Ser Thr Leu Thr Pro Thr Ala Thr Tyr Ser Gly Gly
25 30 35

5 GTT ACC GAC TAC GCT TCC ACC TTC GGT ATT GCC GTT CAA
CCA ATC TCC 558
Val Thr Asp Tyr Ala Ser Thr Phe Gly Ile Ala Val Gln Pro Ile Ser
40 45 50

10 ACT ACA TCC AGC GCA TCA TCT GCA GCC ACC ACA GCC TCA
TCT AAG GCC 606
Thr Thr Ser Ser Ala Ser Ser Ala Ala Thr Thr Ala Ser Ser Lys Ala
15 55 60 65 70

AAG AGA GCT GCT TCC CAA ATT GGT GAT GGT CAA GTC CAA
20 GCT GCT ACC 654
Lys Arg Ala Ala Ser Gln Ile Gly Asp Gly Gln Val Gln Ala Ala Thr
75 80 85

25 ACT ACT GCT TCT GTC TCT ACC AAG AGT ACC GCT GCC GCC
GTT TCT CAG 702
Thr Thr Ala Ser Val Ser Thr Lys Ser Thr Ala Ala Ala Val Ser Gln
90 95 100

30 ATC GGT GAT GGT CAA ATC CAA GCT ACT ACT AAG ACT ACC
GCT GCT GCT 750
Ile Gly Asp Gly Gln Ile Gln Ala Thr Thr Lys Thr Thr Ala Ala Ala
105 110 115

35 GTC TCT CAA ATT GGT GAT GGT CAA ATT CAA GCT ACC ACC
AAG ACT ACC 798
Val Ser Gln Ile Gly Asp Gly Gln Ile Gln Ala Thr Thr Lys Thr Thr
40 120 125 130

45 TCT GCT AAG ACT ACC GCC GCT GCC GTT TCT CAA ATC AGT
GAT GGT CAA 846
Ser Ala Lys Thr Thr Ala Ala Ala Val Ser Gln Ile Ser Asp Gly Gln
135 140 145 150

50 ATC CAA GCT ACC ACC ACT ACT TTA GCC CCA AAG AGC ACC
GCT GCT GCC 894
Ile Gln Ala Thr Thr Thr Leu Ala Pro Lys Ser Thr Ala Ala Ala
155 160 165

55 GTT TCT CAA ATC GGT GAT GGT CAA GTT CAA GCT ACC ACC

ACT ACT TTA 942

Val Ser Gln Ile Gly Asp Gly Gln Val Gln Ala Thr Thr Thr Leu

5

170

175

180

GCC CCA AAG AGC ACC GCT GCT GCC GTT TCT CAA ATC GGT

GAT GGT CAA 990

10

Ala Pro Lys Ser Thr Ala Ala Ala Val Ser Gln Ile Gly Asp Gly Gln

185

190

195

GTT CAA GCT ACT ACT AAG ACT ACC GCT GCT GCT GTC TTT

CAA ATT GGT 1038

15

Val Gln Ala Thr Thr Lys Thr Thr Ala Ala Ala Val Phe Gln Ile Gly

200

205

210

GAT GGT CAA GTT CTT GCT ACC ACC AAG ACT ACT CGT GCC

GCC GTT TCT 1086

20

Asp Gly Gln Val Leu Ala Thr Thr Lys Thr Thr Arg Ala Ala Val Ser

215

220

225

230

CAA ATC GGT GAT GGT CAA GTT CAA GCT ACT ACC AAG ACT

ACC GCT GCT 1134

25

Gln Ile Gly Asp Gly Gln Val Gln Ala Thr Thr Lys Thr Thr Ala Ala

235

240

245

GCT GTC TCT CAA ATC GGT GAT GGT CAA GTT CAA GCA ACT

ACC AAA ACC 1182

35

Ala Val Ser Gln Ile Gly Asp Gly Gln Val Gln Ala Thr Thr Lys Thr

250

255

260

ACT GCC GCA GCT GTT TCC CAA ATT ACT GAC GGT CAA GTT

CAA GCC ACT 1230

40

Thr Ala Ala Ala Val Ser Gln Ile Thr Asp Gly Gln Val Gln Ala Thr

265

270

275

ACA AAA ACC ACT CAA GCA GCC AGC CAA GTA AGC GAT GGC

CAA GTC CAA 1278

45

Thr Lys Thr Thr Gln Ala Ala Ser Gln Val Ser Asp Gly Gln Val Gln

280

285

290

GCT ACT ACT GCT ACT TCC GCT TCT GCA GCC GCT ACC TCC

ACT GAC CCA 1326

50

Ala Thr Thr Ala Thr Ser Ala Ser Ala Ala Ala Thr Ser Thr Asp Pro

295

300

305

310

55

GTC GAT GCT GTC TCC TGT AAG ACT TCT GGT ACC TTA GAA
ATG AAC TTA 1374

Val Asp Ala Val Ser Cys Lys Thr Ser Gly Thr Leu Glu Met Asn Leu
315 320 325

AAG GGC GGT ATC TTA ACT GAC GGT AAG GGT AGA ATT GGT
TCT ATT GTT 1422

Lys Gly Gly Ile Leu Thr Asp Gly Lys Gly Arg Ile Gly Ser Ile Val
330 335 340

GCT AAC AGA CAA TTC CAA TTT GAC GGT CCA CCA CCA CAA
GCT GGT GCC 1470

Ala Asn Arg Gln Phe Gln Phe Asp Gly Pro Pro Pro Gln Ala Gly Ala
345 350 355

ATC TAC GCT GCT GGT TGG TCT ATA ACT CCA GAC GGT AAC
TTG GCT ATT 1518

Ile Tyr Ala Ala Gly Trp Ser Ile Thr Pro Asp Gly Asn Leu Ala Ile
360 365 370

GGT GAC AAT GAT GTC TTC TAC CAA TGT TTG TCC GGT ACT
TTC TAC AAC 1566

Gly Asp Asn Asp Val Phe Tyr Gln Cys Leu Ser Gly Thr Phe Tyr Asn
375 380 385 390

TTG TAC GAC GAA CAC ATT GGT AGT CAA TGT ACT CCA GTC
CAC TTG GAA 1614

Leu Tyr Asp Glu His Ile Gly Ser Gln Cys Thr Pro Val His Leu Glu
395 400 405

GCT ATC GAT TTG ATA GAC TGT TAAGCAGAAA ACTATTAGTT
CTTTTATCCT 1665

Ala Ile Asp Leu Ile Asp Cys
410

GATGACTTTT TCTCATTTCG ATTGATTAGA AAGGAAAAAA
AGAAGTGTCC TTTTCTACTA 1725

CTACTCTAGT CGCATCCATT CCTTTGCATT TATCTTTTCT
GCGGTTGGCC AATCCATTCT 1785

TCCGAGAATT TGGCTAGCCA TACTTGATGT TTTCCCATTA
TTGGTTCGTT TGGCAATGCT 1845

AATTTTCTTA ATTGCCCCTT ATATACTCTT CCATAAAATG
TTTTTTTTAT AACTAATTTT 1905

5

CTGTATATCA TTATCTAATA ATCTTATAAA ATGTTAAAAA
GACTTGGAAA GCAACGAGTG 1965

10

ATCGTGACCA CATAATTGCC TCGCTACACG GCAAAAATAA
GCCAGTCCTA ATGTGTATAT 2025

15

TAAAGGCTGC ATGTGGCTAC GTC
2048

(2) INFORMATION FOR SEQ ID NO: 6:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 413 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

30

Met Gln Tyr Lys Lys Thr Leu Val Ala Ser Ala Leu Ala Ala Thr Thr
1 5 10 15

35

Leu Ala Ala Tyr Ala Pro Ser Glu Pro Trp Ser Thr Leu Thr Pro Thr
20 25 30

40

Ala Thr Tyr Ser Gly Gly Val Thr Asp Tyr Ala Ser Thr Phe Gly Ile
35 40 45

45

Ala Val Gln Pro Ile Ser Thr Thr Ser Ser Ala Ser Ser Ala Ala Thr
50 55 60

Thr Ala Ser Ser Lys Ala Lys Arg Ala Ala Ser Gln Ile Gly Asp Gly
65 70 75 80

50

Gln Val Gln Ala Ala Thr Thr Thr Ala Ser Val Ser Thr Lys Ser Thr
85 90 95

55

Ala Ala Ala Val Ser Gln Ile Gly Asp Gly Gln Ile Gln Ala Thr Thr
100 105 110

Lys Thr Thr Ala Ala Ala Val Ser Gln Ile Gly Asp Gly Gln Ile Gln
115 120 125

5

Ala Thr Thr Lys Thr Thr Ser Ala Lys Thr Thr Ala Ala Ala Val Ser
130 135 140

10

Gln Ile Ser Asp Gly Gln Ile Gln Ala Thr Thr Thr Thr Leu Ala Pro
145 150 155 160

15

Lys Ser Thr Ala Ala Ala Val Ser Gln Ile Gly Asp Gly Gln Val Gln
165 170 175

Ala Thr Thr Thr Thr Leu Ala Pro Lys Ser Thr Ala Ala Ala Val Ser
180 185 190

20

Gln Ile Gly Asp Gly Gln Val Gln Ala Thr Thr Lys Thr Thr Ala Ala
195 200 205

25

Ala Val Phe Gln Ile Gly Asp Gly Gln Val Leu Ala Thr Thr Lys Thr
210 215 220

Thr Arg Ala Ala Val Ser Gln Ile Gly Asp Gly Gln Val Gln Ala Thr
225 230 235 240

30

Thr Lys Thr Thr Ala Ala Ala Val Ser Gln Ile Gly Asp Gly Gln Val
245 250 255

35

Gln Ala Thr Thr Lys Thr Thr Ala Ala Ala Val Ser Gln Ile Thr Asp
260 265 270

40

Gly Gln Val Gln Ala Thr Thr Lys Thr Thr Gln Ala Ala Ser Gln Val
275 280 285

Ser Asp Gly Gln Val Gln Ala Thr Thr Ala Thr Ser Ala Ser Ala Ala
290 295 300

45

Ala Thr Ser Thr Asp Pro Val Asp Ala Val Ser Cys Lys Thr Ser Gly
305 310 315 320

50

Thr Leu Glu Met Asn Leu Lys Gly Gly Ile Leu Thr Asp Gly Lys Gly
325 330 335

Arg Ile Gly Ser Ile Val Ala Asn Arg Gln Phe Gln Phe Asp Gly Pro
340 345 350

55

Pro Pro Gln Ala Gly Ala Ile Tyr Ala Ala Gly Trp Ser Ile Thr Pro
 355 360 365

Asp Gly Asn Leu Ala Ile Gly Asp Asn Asp Val Phe Tyr Gln Cys Leu
 370 375 380

Ser Gly Thr Phe Tyr Asn Leu Tyr Asp Glu His Ile Gly Ser Gln Cys
 385 390 395 400

Thr Pro Val His Leu Glu Ala Ile Asp Leu Ile Asp Cys
 405 410

Claims

1. A process for preparing a recombinant albumin from yeast, comprising culturing the yeast and obtaining the albumin, characterised in that the yeast is deficient in heat shock protein 150 (Hsp150).
2. A process according to Claim 1 wherein the yeast has a defect in its genome such that a reduced level of the Hsp150 protein is produced.
3. A process for preparing a recombinant albumin from yeast, comprising culturing the yeast and obtaining the albumin, characterised in that no Hsp150 protein is produced by the yeast.
4. A process according to any one of Claims 1 to 3 wherein the albumin is a human albumin.
5. A process according to any one of the preceding claims wherein the yeast is a *Torulaspora*, *Kluyveromyces*, *Schizosaccharomyces*, *Pichia* or *Saccharomyces* species.
6. A process according to Claim 5 wherein the yeast is *S. cerevisiae*.
7. A process according to any one of the preceding claims wherein the recombinant albumin is secreted from the yeast into the surrounding medium and purified therefrom.
8. A yeast transformed to express a recombinant albumin characterised in that the yeast is deficient in Hsp150.
9. A yeast according to Claim 8 wherein the yeast has a defect in its genome such that a reduced level of the Hsp150 protein is produced.
10. A yeast according to Claim 8 wherein substantially no Hsp150 protein is produced by the yeast.
11. A yeast according to any one of Claims 8 to 10 wherein the albumin is a human albumin.
12. A yeast according to any one of Claims 8 to 11 wherein the yeast is *Torulaspora*, *Kluyveromyces*, *Schizosaccharomyces* or *Saccharomyces* species.
13. A yeast according to Claim 12 wherein the yeast is *S. cerevisiae*.
14. A yeast according to any one of Claims 8 to 13 wherein the yeast is transformed with a DNA construct such that the recombinant albumin is secreted from the yeast during culturing thereof.
15. A method of preparing a yeast according to any one of Claims 8 to 14 comprising the steps of

(i) transforming the yeast with a coding sequence for expression of the recombinant albumin, and

(ii) disrupting the genome of the yeast such that the yeast has an abnormally low level of Hsp150,

5 wherein steps (i) and (ii) may be carried out in either order or simultaneously.

Patentansprüche

10 1. Verfahren zum Herstellen eines rekombinanten Albumins aus Hefe, welches das Kultivieren der Hefe und das Gewinnen des Albumins umfaßt, **dadurch gekennzeichnet**, daß es der Hefe an Hitzeschockprotein 150 (Hsp150) mangelt.

15 2. Verfahren nach Anspruch 1, wobei die Hefe einen Defekt in ihrem Genom aufweist, so daß ein reduziertes Niveau an Hsp150-Protein erzeugt wird.

3. Verfahren zum Herstellen eines rekombinanten Albumins aus Hefe, welches das Kultivieren der Hefe und das Gewinnen des Albumins umfaßt, **dadurch gekennzeichnet**, daß kein Hsp150-Protein von der Hefe erzeugt wird.

20 4. Verfahren nach einem der Ansprüche 1 bis 3, wobei das Albumin ein humanes Albumin ist.

5. Verfahren nach einem der vorangehenden Ansprüche, wobei die Hefe eine *Torulaspora*-, *Kluyveromyces*-, *Schizosaccharomyces*-, *Pichia*- oder *Saccharomyces*-Spezies ist.

25 6. Verfahren nach Anspruch 5, wobei die Hefe *S. cerevisia* ist.

7. Verfahren nach einem der vorangehenden Ansprüche, wobei das rekombinante Albumin von der Hefe in das umgebende Medium sekretiert wird und hieraus aufgereinigt wird.

30 8. Hefe transformiert zum Expressieren eines rekombinanten Albumins, **dadurch gekennzeichnet**, daß es der Hefe an Hsp150 mangelt.

9. Hefe nach Anspruch 8, wobei die Hefe einen Defekt in ihrem Genom aufweist, so daß ein reduziertes Niveau an Hsp150-Protein erzeugt wird.

35 10. Hefe nach Anspruch 8, wobei im wesentlichen kein Hsp150-Protein von der Hefe erzeugt wird.

11. Hefe nach einem der Ansprüche 8 bis 10, wobei das Albumin ein humanes Albumin ist.

40 12. Verfahren nach einem der Ansprüche 8 bis 11, wobei die Hefe eine *Torulaspora*-, *Kluyveromyces*-, *Schizosaccharomyces*- oder *Saccharomyces*-Spezies ist.

13. Hefe nach Anspruch 12, wobei die Hefe *S. cerevisiae* ist.

45 14. Hefe nach einem der Ansprüche 8 bis 13, wobei die Hefe mit einem DNA-Konstrukt transformiert ist, so daß das rekombinante Albumin von der Hefe sekretiert wird, während sie kultiviert wird.

15. Verfahren zum Herstellen einer Hefe nach einem der Ansprüche 8 bis 14, welches die Schritte aufweist:

50 (i) Transformieren der Hefe mit einer codierenden Sequenz für die Expression des rekombinanten Albumins und

(ii) Unterbrechen des Genoms der Hefe, so daß die Hefe ein abnormal niedriges Niveau an Hsp150 aufweist,

55 wobei die Schritte (i) und (ii) in jeder Reihenfolge oder gleichzeitig ausgeführt werden können.

Revendications

1. Procédé de préparation d'une albumine recombinante à partir d'une levure, comprenant la culture de la levure et l'obtention de l'albumine, caractérisé en ce que la levure est déficiente en protéine de choc thermique 150 (Hsp150).
2. Procédé selon la revendication 1, dans lequel la levure a un défaut dans son génome, de telle sorte qu'un niveau réduit de la protéine Hsp150 est produit.
3. Procédé de préparation d'une albumine recombinante à partir d'une levure, comprenant la culture de la levure et l'obtention de l'albumine, caractérisé en ce qu'aucune protéine Hsp150 n'est produite par la levure.
4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel l'albumine est une albumine humaine.
5. Procédé selon l'une quelconque des revendications précédentes, dans lequel la levure est une espèce *Torulaspora*, *Kluyveromyces*, *Schizosaccharomyces*, *Pichia* ou *Saccharomyces*.
6. Procédé selon la revendication 5, dans lequel la levure est *S. Cerevisiae*.
7. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'albumine recombinante est sécrétée par la levure dans le milieu environnant et est purifiée à partir de celui-ci.
8. Levure transformée afin d'exprimer une albumine recombinante, caractérisée en ce que la levure est déficiente en Hsp150.
9. Levure selon la revendication 8, dans laquelle la levure a un défaut dans son génome, de telle sorte qu'un niveau réduit de la protéine Hsp150 est produit.
10. Levure selon la revendication 8, dans laquelle sensiblement aucune protéine Hsp150 n'est produite par la levure.
11. Levure selon l'une quelconque des revendications 8 à 10, dans laquelle l'albumine est une albumine humaine.
12. Levure selon l'une quelconque des revendications 8 à 11, dans laquelle la levure est une espèce *Torulaspora*, *Kluyveromyces*, *Schizosaccharomyces* ou *Saccharomyces*.
13. Levure selon la revendication 12, dans laquelle la levure est *S. Cerevisiae*.
14. Levure selon l'une quelconque des revendications 8 à 13, dans laquelle la levure est transformée avec une structure d'ADN, de telle sorte que l'albumine recombinante est sécrétée par la levure pendant sa culture.
15. Méthode de préparation d'une levure selon l'une quelconque des revendications 8 à 14, comprenant les étapes de :
 - i) transformation de la levure avec une séquence de codage pour l'expression de l'albumine recombinante ; et
 - ii) cassure du génome de la levure de telle sorte que la levure a un niveau anormalement bas de Hsp150,dans laquelle les étapes (i) et (ii) peuvent être effectuées dans n'importe quel ordre ou simultanément.

5' and 3' regions of *HSP150* gene obtained by PCR:




Figure 1

Figure 1 cont'd






Fig 2



Ligate *Cla* I / *Sal* I *URA3* fragment into *Cla* I / *Xho* I cut pAYE 505



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.